Filing Procedures. Persons with questions regarding filing should contact the Secretary (202–205–2000).

Any person desiring to submit a document to the Commission in confidence must request confidential treatment. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. All such requests should be directed to the Secretary to the Commission and must include a full statement of the reasons why the Commission should grant such treatment. See 19 CFR 201.6. Documents for which confidential treatment by the Commission is properly sought will be treated accordingly.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of these registrants to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each of the company’s maintenance of effective controls against diversion by inspecting and testing each company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed companies.

Dated: July 19, 2018.

John J. Martin,
Assistant Administrator.

[FR Doc. 2018–15959 Filed 7–25–18; 8:45 am]
BILLY CODE 7020–02–P

DEPARTMENT OF JUSTICE
Drug Enforcement Administration

[DOcket No. DEA–392]

Bulk Manufacturer of Controlled Substances Registration

ACTION: Notice of registration.

SUMMARY: Registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturers of various classes of schedule I and II controlled substances.

SUPPLEMENTARY INFORMATION: The companies listed below applied to be registered as bulk manufacturers of various basic classes of controlled substances. Information on previously published notices are listed in the table below. No comments or objections were submitted for these notices.

<table>
<thead>
<tr>
<th>Company</th>
<th>FR docket</th>
<th>Published</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cedarburg Pharmaceuticals, Inc</td>
<td>83 FR 5275</td>
<td>February 6, 2018</td>
</tr>
<tr>
<td>Cayman Chemical Company</td>
<td>83 FR 17678</td>
<td>April 23, 2018</td>
</tr>
</tbody>
</table>

For further information contact: If you have additional comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Lauren Alder Reid, Chief, Immigration Law Division, Office of Policy, Executive Office for Immigration Review, 5107 Leesburg Pike, Suite 2500, Falls Church, VA 22041, telephone: (703) 305–0289.

SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points:

—Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Executive Office for Immigration Review, including whether the information will have practical utility;

—Evaluate whether the proposed collection of information burdens or impacts the repetition or mechanization of the collection of information;

—Evaluate the accuracy of the agency's estimates of the burden of the proposed collection of information;

—Suggest the precise scope of the collection of information and what is required.

All contract personnel will sign appropriate nondisclosure agreements.
